GSK Articles
US court rules in GlaxoSmithKline’s favor in Arzerra patent dispute
18 November 2011
GlaxoSmithKline’s albiglutide fails to show superiority over Novo Nordisk’s Victoza
18 November 2011
EU Pharma re-rating stalled against EU market vis-a-vis defensives, says Nomura analyst
13 November 2011
GlaxoSmithKline finalizes $3 billion deal with US government over marketing practices
4 November 2011
GlaxoSmithKline posts solid 3rd-qtr results, in line with expectations; joins WIPO scheme
27 October 2011
Benlysta to drive lupus drug market to $2.1 billion in 2020
26 October 2011
GlaxoSmithKline warned by US FDA over cGMP violations at UK plant; positive malaria vaccine news
20 October 2011
Epizyme earns $4 million pre-clinical milestone from GSK under novel HMT therapeutics alliance
17 October 2011
ViiV Healthcare announces 16 new grantees for 2011/2012 to prevent mother-to-child HIV transmission
13 October 2011
In India, Lilly and Boehringer link for diabetes drug marketing; GSK eyeing acquisitions
4 October 2011
UK NICE negative on Sanofi’s Jevtana and GSK’s Benlysta but positive on ALK-Abello’s Pharmalgen
30 September 2011
Medicines Australia starts new Code of Conduct review
26 September 2011
ViiV Healthcare withdraws applications of once-daily Celsentri/Selzentry
21 September 2011
Amgen’s Prolia increases bone mineral density over eight; new indications approved
20 September 2011
Prosensa to get milestone payments from GSK under Duchenne collaboration
16 September 2011
US FDA warns of heart rhythm problems with GSK’s anti-nausea drug Zofran
16 September 2011
Impax confirms patent challenge to GlaxoSmithKline’s Jalyn; Albemarle hikes API prices
14 September 2011
New twist in diabetes drugs could reduce life-threatening side effects
12 September 2011
GlaxoSmithKline partners with BARDA to develop new class of antibiotic; amends deal with Anacor
8 September 2011
GlaxoSmithKline gets 25% stake in spin-out firm Autifony
23 August 2011
Positive top-line Ph III results of Impax and GSK IPX066 in advanced Parkinson’s disease
16 August 2011
FDA filings for Ironwood and Forest for linaclotide, and GSK and XenoPort for Horizant ER
10 August 2011
Benlysta heading in right direction, but uptake slower than originally expected, says BioTrends
7 August 2011
Nabi plunges as NicVAX flops in Ph III trial
19 July 2011
EU approval for GlaxoSmithKline and Human Genome’s Benlysta; Slowing Advair sales in USA
15 July 2011
GlaxoSmithKline gets US FDA approval for Boostrix to prevent tetanus, diphtheria and pertussis in older people
11 July 2011
Pharma’s differentiated strategies for evolving health care landscape presented at Nomura conference
5 July 2011
More Japanese drug OKs: GSK’s Rotarix and Lamictal; Takeda’s Liovel and new use for Eisai/Abbott’s Humira
4 July 2011
Natco joins forces with Lupin to sell generic Tykerb; gets orphan status for cancer drug candidate
24 June 2011
Concert gets $4 million milestone in GlaxoSmithKline collaboration; progresses drug candidates
21 June 2011
GSK’s Relovair likely to emerge as market leader among once-daily LABA/ICS combinations
19 June 2011
PATH MVI partners with GSK and Crucell to develop second-generation vaccine against malaria
8 June 2011
ASCO highlights include GSK’s pazopanib, Novartis’ INC424 and Glivec, B-MS/Otsuka’s Sprycel
6 June 2011
Slew of good news from EMA advisory panel for Benlysta, Fampyra, Vibativ, Victrelis, Xgeva and Yervoy
23 May 2011
GlaxoSmithKline 1st-qtr 2011 sales and earnings down but firm back in the black; Lovaza subpoena
28 April 2011
EMA updates Rxing advice for GlaxoSmithKline’s Pandemrix reflecting possible narcolepsy link
18 April 2011
GlaxoSmithKline to shed OTC brands, including Alli, as US consumer group calls for the latter to be banned
18 April 2011
GlaxoSmithKline gains EU appro for epilepsy drug Trobalt; Lovaza patent accord; gets $3.5M from Abbott
31 March 2011
AFFiRiS Alzheimer's vaccine promising in Ph I study
14 March 2011
GlaxoSmithKline pulls out of Targacept alliance
4 March 2011
US FDA clears Takeda’s Edarbi for hypertension and grants full approval for GSK’s Promacta
28 February 2011
UK’s NICE backs NHS use of GlaxoSmithKline’s kidney cancer drug Votrient but again turns down Roche’s Avastin for breast cancer
24 February 2011
Rheumatologists’ uptake of Benlysta will not lead to decline in patient share for immunosuppressant/cytotoxics or for Rituxan through 2013
24 February 2011
Merck Serono pulls European application for oral MS drug Movectro; Sun withdraws topotecan
18 February 2011
As GSK and Pfizer roll out pneumococcal vaccines in Kenya, MSF asks are donors getting a fair deal?
11 February 2011
WHO says narcolepsy link with GSK’s flu vaccine Pandemrix needs further investigation
10 February 2011
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
